ArticleExperimental and therapeutic medicine2015
Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- The role of SOX2 overexpression in prognosis of patients with solid tumors: A meta-analysis and system review.Medicine · 2020Pooled it
- Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.BioMed research international · 2017Pooled it
- Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets.Pharmaceuticals (Basel, Switzerland) · 2025Article
- miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.Scientific reports · 2024Article
- Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide.Molecular neurobiology · 2024Article
- Differential Expression of SRY-Related HMG-Box Transcription Factor 2, Oligodendrocyte Lineage Transcription Factor 2, and Zinc Finger E-Box Binding Homeobox 1 in Serum-Derived Extracellular Vesicles: Implications for Mithramycin Sensitivity and Targeted Therapy in High-Grade Glioma.ACS pharmacology & translational science · 2024Article
- Glioma SOX2 expression decreased after adjuvant therapy.BMC cancer · 2019Article
- Knockdown of miR-429 Attenuates Aβ-Induced Neuronal Damage by Targeting SOX2 and BCL2 in Mouse Cortical Neurons.Neurochemical research · 2018Article
- The clinicopathological significance of CD133 and Sox2 in astrocytic glioma.Cancer biomarkers : section A of Disease markers · 2018Article
- In situ characterization of stem cells-like biomarkers in meningiomas.Cancer cell international · 2018Article
- The miR-200 family: multiple effects on gliomas.Cancer management and research · 2018Review
- MicroRNA-200b expression level is negatively associated with pathological grading in human gliomas.Cancer management and research · 2018Article
- Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the associations between microRNA (miR)-200b and sex determining region Y-box 2 (SOX2) expression with gender, age, clinical staging and pathological staging in 123 patients with glioma. The results revealed higher miR-200b expression levels in the glioma tissue than in the normal brain tissues, and a reduction in miR-200b expression with increasing pathological grading of the gliomas. Immunohistochemistry revealed a 53.7% gross expression rate of SOX2 in the glioma tissues. SOX2 and miR-200b expression levels were significantly correlated with the histological grading of the gliomas (P<0.05); however, no associations were observed with patient gender, age, pathological classification or clinical staging of the glioma (P>0.05). In patients with grade I and II gliomas, no correlation was detected between miR-200b and SOX2, while a significant correlation was observed in grade III and IV gliomas. A median 52-month follow-up revealed 1-, 3- and 5-year gross survival rates of 82.1, 50.0 and 30.7%, respectively, in the 123 patients with a glioma. Univariate analysis revealed no association between survival rate and patient age, gender, Karnofsky Performance Scale score, histological grading or clinical staging (P>0.05). However, miR-200b and SOX2 were independent prognostic factors for glioma (P<0.05). Patients with positive SOX2 expression exhibited a significantly reduced 5-year survival rate, compared with those with negative SOX2 expression (P<0.001). Furthermore, a significantly higher 5-year survival rate was observed in patients with high miR-200b expression than those with low miR-200b expression (P<0.001). The results indicated that SOX2 and miR-200b expression levels are associated with the histological grading of gliomas, but do not correlate with patient gender or age, or the pathological classification or clinical staging of the gliomas. Thus, miR-200b and SOX2 offer useful independent prognostic factors for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.